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Summary 
● The process of developing a new therapeutic is long, expensive, and risky.  
● Current small animal models are often poor representations of human disease, contributing 
to the high rate of failure in human trials. 
● Outbred dogs can be excellent models for researching human disease. 
● Clinical trials in dogs are inexpensive and efficient compared with human trials. 
● Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, 
provides one case study on how trials in dogs can help advance trials in humans. 
Introduction 
The process of developing a new therapeutic is expensive, time-consuming, and uncertain. On 
average, it takes nine years (Kaitin) and costs more than $1 billion (DiMasi et al.; Adams and 
Brantner) to take a new therapy through clinical development. Despite this significant investment, 
only approximately 10% (Hay et al.) of Investigational New Drugs (INDs) submitted to the Food 
and Drug Administration (FDA) are ultimately approved, with the majority of failures due to a 
lack of efficacy. Therefore, investors in novel therapeutics are constantly looking for therapies that 
have the best chance of succeeding in clinical trials. For academic investigators trying to raise 
money for human trials of their novel therapeutic, generating early data that show their therapeutic 
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ANIMAL MEDICAL THERAPEUTICS 
has a greater than average chance of success can significantly improve their ability to obtain fund-
ing. Unfortunately, it is very difficult to generate truly differentiated data using current small 
animal models. 
 
An emerging avenue for improving preclinical efficacy estimates is clinical trials on pet dogs. For 
certain diseases, pet dogs serve as an excellent disease model to efficiently and inexpensively 
reduce the risk of a new therapeutic. In this chapter, we present the rationale for using pet dogs, 
details on why pet dogs can be a good model, a brief overview of the logistics of running pet dog 
trials, and a case study on how this approach has been used to advance one immunotherapeutic 
into human trials.   
Current Small Animal Models Are Often Poor 
Representations of Human Disease 
For decades, mice have served as the foundation of preclinical research on human diseases. Mice 
are easy to manipulate genetically and have short lifespans, making them excellent tools for 
probing the biological mechanisms of disease. While this approach has driven the synthesis and 
development of many novel therapeutics, drugs that are effective in mice too often fail to work in 
humans. A number of reasons have been proposed as to why mouse findings do not translate to 
humans: (1) research mice are only ~85% similar to humans in the protein-coding regions of their 
genomes, (2) mice are often engineered to express target genes in nonphysiologic ways, (3) mice 
are inbred, (4) mice are raised in laboratory environments and thus not exposed to the same 
environments as people, and (5) mice can withstand dosages of drugs that would be extremely 
toxic in humans. Altogether, these issues limit the ability of murine models to predict the safety 
and therapeutic efficacy of novel agents in human patients. Nevertheless, it is nearly impossible to 
advance a therapy into human trials without positive evidence in mice. 
Outbred Dogs Can Be Excellent Models of Human 
Disease 
Unlike laboratory animals, pet dogs spontaneously develop many of the same diseases that humans 
do, including narcolepsy, psychiatric disorders, osteoarthritis, and cancer (Lin et al.; Tang et al.; 
Kosinska et al.; Simpson et al.). Also, unlike laboratory mice, pet animals share the same environ-
mental exposures as humans and have not undergone any artificial genetic manipulation. As such, 
pet dogs develop diseases with a very similar pathogenesis to those in humans. The most well-
characterized similarities between dog and human diseases are in cancers, including melanoma, 
osteosarcoma, and lymphoma. In each of these cancers, dogs have been found to spontaneously 
develop tumors whose clinical presentation, biological behavior, and genetic aberrancies 
(mutations and chromosomal translocations) are very similar to their human counterparts. Thus 
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pet dogs with spontaneous diseases more faithfully represent the pathogenesis of human diseases 
than do laboratory mice.  
 
Beyond having very similar disease pathogenesis, dogs as a species are in many ways more similar 
to humans than mice are. Dogs have a longer lifespan than mice, are phylogenetically closer to 
humans than mice are, and experience similar side effects and toxicities to drugs as humans do 
(Paoloni and Khanna; National Academies of Sciences, Engineering, and Medicine). In fact, 
laboratory dogs are already used in preclinical toxicity studies to help ensure new therapies are 
safe to test on humans. There are 70–80 million dogs in the United States, of which ~20% will 
develop osteoarthritis and ~25% will die of cancer. These canine patients require treatment, and 
studying the outcomes of their treatment can inform human clinical trials. In addition to the bene-
fits they provide to humans, pet trials provide owners with free access to cutting-edge therapies 
for their dogs and the chance to improve the health and wellbeing of their pets. Pet dogs routinely 
receive the same breadth of clinical interventions as humans, including surgery, radiation, and 
chemotherapy (Figure 1), and so can serve as research subjects in trials for a broad range of ther-
apies (see the chapter “Pre-clinical Animal Models”).  
 
Figure 1. Multiple Types of Therapies Can Be Evaluated in Pet Dogs.  
 
 
 
Legend: Images of pet dogs undergoing treatment with (A) surgery, (B) radiation, and (C) 
chemotherapy and immunotherapy.   
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Clinical Trials in Pet Dogs 
Inexpensive and efficient compared with human trials 
Not only do pet dogs recapitulate human diseases more accurately than murine models, but clinical 
trials in pet dogs are an efficient way to evaluate therapeutic safety, efficacy and inform human 
clinical trial design (Table 1). Unlike human trials, clinical trials in pets are governed primarily by 
the United States Department of Agriculture (USDA) under the Animal Welfare Act (AWA). 
Under this act, trials need the approval of only the Institutional Animal Care and Use Committee 
(IACUC). As such, trial approval can occur within months or even weeks, without extensive fed-
eral review. Moreover, because dogs have a shorter lifespan than humans and age five to eight 
times faster, their diseases often progress faster, allowing for a more rapid evaluation of treatment 
efficacy. Overall, this faster, shorter trial process makes trials in pet dogs significantly less expen-
sive than human trials. Relative to mouse experiments, dog trials do require significantly more 
drugs and are more expensive to conduct. However, the improved efficacy signals from dogs can 
improve the chances of success for the even more expensive human trials that follow. Moreover, 
initiating dog trials before human trials might allow investigators to identify and appropriately 
adjust for safety signals in dogs prior to beginning human trials, thus increasing the likelihood of 
delivering a therapeutic dose and reducing the safety risk in human trials. 
 
Table 1. Comparison of Research Trials for Evaluation of New Therapeutics. 
 
 
 
Additional considerations 
The timing of trials in pet dogs is critical to minimizing risk in human trials. Any adverse event or 
safety outcome found in a dog trial that was initiated after submission of an IND to the FDA must 
be reported to the FDA (see the chapter “FDA Drug Regulation: Investigational New Drug 
Applications”). Because dog trials are often non-randomized and performed with sick dogs, there 
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is a risk that adverse events associated with the natural progression of the disease might impact the 
therapy’s perceived safety in humans. Therefore, for optimal benefit, dog trials should be started 
prior to human trials, allowing investigators to identify and appropriately adjust for safety signals 
in dogs without placing ongoing human programs at risk.  
 
Commercial benefits  
Clinical trials in dogs are not only tools for developing more efficient and easier-to-fund human 
trials. If designed properly, clinical trials in pet dogs can be used to commercialize therapeutics in 
dogs. To have this opportunity for small molecules, investigators must file an investigational new 
animal drug (INAD) application with the FDA’s Center for Veterinary Medicine (CVM) and 
ensure agreement with regulators on trial design and reporting (see the chapter “FDA Drug Regu-
lation: Investigational New Drug Applications”). These requirements will slow the trial timeline, 
but the upside of following them may be worthwhile for certain therapies. New veterinary biolog-
ics are currently governed by the USDA and thus do not require FDA approval to have commercial 
potential. 
 
Case study: Advaxis 
Advaxis, a clinical-stage biotechnology company that focuses on developing cancer 
immunotherapies, has used studies in pet dogs to enhance the development of a Listeria mono-
cytogenes–based platform technology (Wood and Paterson). The company developed a Listeria-
based immunotherapeutic that expresses HER2/neu (ADXS31-164) and initially generated exten-
sive preclinical data in murine cancer models. As further proof of therapeutic efficacy, Advaxis 
funded an investigation of whether ADXS31-164 could delay or prevent metastatic disease in pet 
dogs with osteosarcoma. Canine osteosarcoma has the same clinical, biological, and molecular 
features as pediatric osteosarcoma, including the expression of the HER2/neu protein, which 
makes it an excellent model for evaluating the safety and therapeutic effects of treatments. The 
trial, carried out at the University of Pennsylvania School of Veterinary Medicine, tested the 
ADXS31-164 vaccine in dogs. The results showed that this immunotherapeutic approach pro-
longed median survival and disease-free survival and was safe and well tolerated (Mason et al.). 
These data have contributed to the ease with which the company has moved forward and raised 
money for human trials of the vaccine targeting HER2/neu in human cancers, including 
osteosarcoma.  
Conclusion 
Clinical trials in pet dogs represent a relatively fast and inexpensive way to (1) better characterize 
which investigational therapeutics will be successful and (2) improve the design of human trials. 
While dogs are not a perfect model for all human diseases, there are many diseases in which dogs 
are an excellent model. In these diseases, trials in pet dogs provide an excellent way to improve 
confidence in potential new therapies and increase the success rate of clinical trials. Investigators 
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trying to advance a new therapy to clinical trials should work with their veterinary colleagues to 
understand whether pet dogs are a good model for the disease being studied and, if so, consider 
testing their therapy on pet dogs as a bridge or supplement to human trials.   
Resources 
1. The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational 
Cancer Research: Workshop Summary (National Academies of Sciences, Engineering, 
and Medicine) 
2. Guiding the Optimal Translation of New Cancer Treatments from Canine to Human 
Cancer Patients (Khanna et al.) 
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